082800 — Vivozon Pharmaceutical Co Balance Sheet
0.000.00%
- KR₩226bn
- KR₩260bn
- KR₩88bn
Annual balance sheet for Vivozon Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 90,677 | 54,255 | 14,800 | 12,391 | 7,777 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 11,683 | 13,448 | 9,788 | 14,183 | 14,409 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 122,404 | 96,333 | 47,562 | 45,138 | 44,407 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 25,228 | 32,807 | 33,968 | 25,521 | 31,814 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 248,159 | 194,471 | 187,074 | 173,647 | 184,449 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 111,570 | 89,023 | 77,817 | 64,779 | 72,211 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 140,356 | 109,350 | 81,237 | 69,580 | 78,022 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| ESOP Debt Guarantee | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 107,803 | 85,120 | 105,838 | 104,067 | 106,427 |
| Total Liabilities & Shareholders' Equity | 248,159 | 194,471 | 187,074 | 173,647 | 184,449 |
| Total Common Shares Outstanding |